Citi analyst Daniel Grosslight says competition is ramping in the weight loss drug space after Novo Nordisk (NVO) revealed a new offer for self-pay patients, providing the two lowest doses of Wegovy or Ozempic for $199 per month. The news reflects increasing competition in cash-pay weight loss drug pricing, but Citi is more surprised by the omission of Hims & Hers (HIMS) from Novo’s partners list, the analyst tells investors in a research note. The firm points out that Hims previously stated it was active discussions with Novo to offer Wegovy on its platform. Citi keeps a Sell rating on Hims & Hers with a $30 price target. The stock closed Monday down 4% to $35.58.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HIMS:
- Sell Rating for Hims & Hers Health Amid Pricing Pressures from Novo Nordisk’s GLP-1 Products
- Hims & Hers Health Announces New Share Buyback Program
- Hims & Hers announces $250M share repurchase program
- Hims & Hers names Deb Autor as Chief Policy Officer
- Sell Rating on Hims & Hers Health Due to Overvaluation and Growth Concerns